Trial Profile
Pharmacogenetic study of FcYRIIIa and HER2 genes in relation to treatment of breast cancer.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Jul 2020
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 27 Jul 2020 Status changed from recruiting to completed.
- 29 Aug 2011 New trial record